Surveillance of Terminal Deoxynucleotidyl Transferase-Positive Cells in Peripheral Blood of Patients with Acute Lymphoblastic Leukemia

  • R. G. Smith
  • M. L. Hetherington
  • P. R. Huntsman
  • G. R. Buchanan
Part of the Developments in Oncology book series (DION, volume 45)


Although 95% of children and 80% of adults with acute lymphoblastic leukemia (ALL) can be expected to achieve complete remission with modern therapy, 40–50% of children and 70–80% of adults will eventually succumb to recurrent disease. Many children with ALL who are cured face an uncertain risk of impaired intellectual function, neuroendocrine abnormalities, decreased reproductive capacity, and second neoplasms such as brain tumors. A current dilemma is how to intensify therapy for the high-risk patient without simultaneously exposing all patients to excessive hazards of treatment. Part of this problem stems from the inaccuracy of risk prediction. The availability of sensitive assays for minimal residual disease would add great precision to risk assignment and permit intensified therapy to be aimed at those patients who need it most. Patients whose disease is under control could be spared unnecessary toxicity. If successful, this type of surveillance could become an important tool in selecting alternate chemotherapy at an earlier point in time than is now possible and could serve as a guide to the most effective form of alternate therapy. Sensitive detection of minimal residual leukemia is needed to quantitate tumor cells in bone marrow before and after purging in order to distinguish between inadequate marrow purging and suboptimal ablative therapy as causes of failure in autologous bone marrow transplantation programs.


Acute Lymphoblastic Leukemia Minimal Residual Disease Lymphoblastic Lymphoma Pediatric Oncology Group Pheral Blood 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stass SA, Schumacher HR, Keneklis TP, Bollum FJ: Terminal deoxynucleotidyl transferase immunofluorescence on bone marrow smears: experience in 156 cases. Am J Clin Pathol 72:898–903, 1979.PubMedGoogle Scholar
  2. 2.
    Bollum FJ: Terminal deoxynucleotidyl transferase as a hematopoietic cell marker, Blood 54:1203–1215, 1979.PubMedGoogle Scholar
  3. 3.
    Janossy G, Bollum FJ, Bradstock KF, McMichael A, Ranson N, Greaves MF: Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol 123:1525–1529, 1979.PubMedGoogle Scholar
  4. 4.
    Froehlich TW, Buchanan GR, Cornet JAM, Sartain PA, Smith RG: Terminal deoxynucleotidyl transferase-containing cells in peripheral blood: implications for the surveillance of patients with lymphoblastic leukemia or lymphoma in remission. Blood 58:214–220, 1981.PubMedGoogle Scholar
  5. 5.
    Bradstock KF, Kerr A, Bollum FJ: Antigenic phenotype of TdT-positive cells in human peripheral blood. Cellular Immunol 90:590–598, 1985.CrossRefGoogle Scholar
  6. 6.
    Roberts M, Greaves M, Janossy G, Sutherland R, Pain C: Acute lymphoblastic leukemia (ALL) associated antigen. I. Expression in different hematopoietic malignancies. Leuk Res 2:105–114, 1978.CrossRefGoogle Scholar
  7. 7.
    Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood 58:648–652, 1981.PubMedGoogle Scholar
  8. 8.
    Buchanan GR, Smith RG: Detection of early relapse and minimal residual disease in children with acute lymphoblastic leukemia by enumeration of terminal deoxynucleotidyl transferase-positive cells in peripheral blood. IN: Minimal Residual Disease in Acute Leukemia, Lowenberg B, Hagenbeek A (eds.), Boston, Martinus Nijhoff Publishers, 1984, pp 83–95.Google Scholar
  9. 9.
    Crist W, Boyett J, Roper M, Pullen J, Metzger R, van Eys J, Ragab A, Starling K, Vietti T, Cooper M: Pre-B cell leukemia responds poorly to treatment: a Pediatric Oncology Group study. Blood 61: 407–414, 1984.Google Scholar
  10. 10.
    Lauer S, Cametta B, Sartain P, Buchanan G, Pinkel D, Krance R, Barella L: Cytosine arabinoside/cyclosphosphamide pulses improve prognosis in childhood T cell acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 2:77, 1983 (abstract).Google Scholar
  11. 11.
    Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PC, Vats T, Duncan MH: Modified LSA2-L2 treatment in 53 children with E-rosette-positive T cell leukemia: results and prognostic factors (a Pediatric Oncology Group study). Blood 60:1159–1168, 1982.PubMedGoogle Scholar
  12. 12.
    Buchanan GR, Crist W, Rivera G: Prolonged second remissions following intensive chemotherapy for first marrow relapse in acute lymphoblastic leukemia. Blood 64(Suppl 1):162a, 1984 (abstract).Google Scholar
  13. 13.
    Smith S, Rivera G: Unpublished data.Google Scholar
  14. 14.
    Van Dongen JJM, Hooijkaas H, Hahlen K, Benne K, Bitter WM, Van der Linde-Pressman AA, Tettero ILM, Van de Rijn M, Hilgers J, Van Zanen GE, Hagemeijer A: Detection of minimal residual disease in TdT positive T cell malignancies by double immunofluorescence staining. IN: Minimal Residual Disease in Acute Leukemia, Lowenberg B, Hagenbeek A (eds), Boston, Martinus Nijhoff Publishers, 1984, pp 67–81.Google Scholar
  15. 15.
    Bradstock KF, Kerr A: Immunological detection of covert leukaemic spread in mediastinal T-cell lymphoblastic lymphoma. Leuk Res 9: 905–911, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1986

Authors and Affiliations

  • R. G. Smith
  • M. L. Hetherington
  • P. R. Huntsman
  • G. R. Buchanan

There are no affiliations available

Personalised recommendations